Epidemiology of community-acquired pneumonia in adults: a population-based study

In this prospective study, the authors assessed the incidence, aetiology, and outcome of patients with community-acquired pneumonia in the general population. From December 1993 to November 1995, a study was performed in a mixed residential-industrial urban population of the "Maresme" region in Barcelona, Spain. All subjects > or =14 yrs of age (annual average population size 74,368 inhabitants) with clinically suspected community-acquired pneumonia were registered. All cases were re-evaluated by chest radiographs on the 5th day of illness and at monthly intervals until complete recovery. Urine and blood samples were obtained for culture and antigen detection. When lower respiratory tract secretions were obtained, these were also cultured. There were 241 patients with community-acquired pneumonia, with an annual incidence rate of 1.62 cases (95% confidence interval, 1.42-1.82) per 1,000 inhabitants. Incidence rates increased by age groups and were higher in males than in females. Of 232 patients with aetiological data, 104 had an identifiable aetiology. A total of 114 pathogens were found (single pathogen 94, two pathogens 10). There were 81 episodes of bacterial infection and 33 of viral infection. The most common pathogens were Streptococcus pneumoniae, Chlamydia pneumoniae, and influenza A and B viruses. No case of Hantavirus infection was found. The rate of hospital admission was 61.4% with a mean+/-SD length of 11.7+/-10.1 days, a mean period of 23.0+/-14.3 days inactivity, and an overall mortality rate of 5%. The high rate of hospital admission, prolonged stay in hospital, and long period of inactivity all continue to constitute a social and health care burden of community-acquired pneumonia.

This article has been cited by other articles:

				S. Kruger, S. Ewig, J. Kunde, A. Hanschmann, R. Marre, N. Suttorp, T. Welte, and on behalf of the CAPNETZ study group C-terminal provasopressin (copeptin) in patients with community-acquired pneumonia--influence of antibiotic pre-treatment: results from the German competence network CAPNETZ J. Antimicrob. Chemother., July 1, 2009; 64(1): 159 - 162. [Abstract] [Full Text] [PDF]

				R Menendez, R Martinez, S Reyes, J Mensa, X Filella, M A Marcos, A Martinez, C Esquinas, P Ramirez, and A Torres Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia Thorax, July 1, 2009; 64(7): 587 - 591. [Abstract] [Full Text] [PDF]

				M. Cabre, M. Serra-Prat, E. Palomera, J. Almirall, R. Pallares, and P. Clave Prevalence and prognostic implications of dysphagia in elderly patients with pneumonia Age Ageing, June 26, 2009; (2009) afp100v1. [Abstract] [Full Text] [PDF]

				H. Endeman, B. L. Herpers, B. A. W. de Jong, G. P. Voorn, J. C. Grutters, H. van Velzen-Blad, and D. H. Biesma Mannose-Binding Lectin Genotypes in Susceptibility to Community-Acquired Pneumonia Chest, December 1, 2008; 134(6): 1135 - 1140. [Abstract] [Full Text] [PDF]

				P. G. Dambrava, A. Torres, X. Valles, J. Mensa, M. A. Marcos, G. Penarroja, M. Camps, R. Estruch, M. Sanchez, R. Menendez, et al. Adherence to guidelines' empirical antibiotic recommendations and community-acquired pneumonia outcome Eur. Respir. J., October 1, 2008; 32(4): 892 - 901. [Abstract] [Full Text] [PDF]

				T. P. Lodise, M. Kinzig-Schippers, G. L. Drusano, U. Loos, F. Vogel, J. Bulitta, M. Hinder, and F. Sorgel Use of Population Pharmacokinetic Modeling and Monte Carlo Simulation To Describe the Pharmacodynamic Profile of Cefditoren in Plasma and Epithelial Lining Fluid Antimicrob. Agents Chemother., June 1, 2008; 52(6): 1945 - 1951. [Abstract] [Full Text] [PDF]

				S. Kruger, S. Ewig, R. Marre, J. Papassotiriou, K. Richter, H. von Baum, N. Suttorp, T. Welte, and on behalf of the CAPNETZ Study Group Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes Eur. Respir. J., February 1, 2008; 31(2): 349 - 355. [Abstract] [Full Text] [PDF]

				C. Garcia-Vidal, E. Calbo, V. Pascual, C. Ferrer, S. Quintana, and J. Garau Effects of systemic steroids in patients with severe community-acquired pneumonia Eur. Respir. J., November 1, 2007; 30(5): 951 - 956. [Abstract] [Full Text] [PDF]

				M. Valencia, J. R. Badia, M. Cavalcanti, M. Ferrer, C. Agusti, J. Angrill, E. Garcia, J. Mensa, M. S. Niederman, and A. Torres Pneumonia Severity Index Class V Patients With Community-Acquired Pneumonia: Characteristics, Outcomes, and Value of Severity Scores Chest, August 1, 2007; 132(2): 515 - 522. [Abstract] [Full Text] [PDF]

				M. L. Briones, J. Blanquer, D. Ferrando, M. L. Blasco, C. Gimeno, and J. Marin Assessment of Analysis of Urinary Pneumococcal Antigen by Immunochromatography for Etiologic Diagnosis of Community-Acquired Pneumonia in Adults Clin. Vaccine Immunol., October 1, 2006; 13(10): 1092 - 1097. [Abstract] [Full Text] [PDF]

				S. Ewig, A. Torres, and M. Woodhead Assessment of pneumonia severity: a European perspective Eur. Respir. J., January 1, 2006; 27(1): 6 - 8. [Full Text] [PDF]

				A. Capelastegui, P. P. Espana, J. M. Quintana, I. Areitio, I. Gorordo, M. Egurrola, and A. Bilbao Validation of a predictive rule for the management of community-acquired pneumonia Eur. Respir. J., January 1, 2006; 27(1): 151 - 157. [Abstract] [Full Text] [PDF]

				A. Vila-Corcoles, O. Ochoa-Gondar, C. Llor, I. Hospital, T. Rodriguez, and A. Gomez Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects Eur. Respir. J., December 1, 2005; 26(6): 1086 - 1091. [Abstract] [Full Text] [PDF]

				M. Bartolome, J. Almirall, J. Morera, G. Pera, V. Ortun, J. Bassa, I. Bolibar, X. Balanzo, A. Verdaguer, and the Maresme Community-Acquired Pneumonia Study Gro A population-based study of the costs of care for community-acquired pneumonia Eur. Respir. J., April 1, 2004; 23(4): 610 - 616. [Abstract] [Full Text] [PDF]

				J. Almirall, I. Bolibar, P. Toran, G. Pera, X. Boquet, X. Balanzo, and G. Sauca Contribution of C-Reactive Protein to the Diagnosis and Assessment of Severity of Community-Acquired Pneumonia Chest, April 1, 2004; 125(4): 1335 - 1342. [Abstract] [Full Text] [PDF]

				R. Menendez, M.J. Cremades, E. Martinez-Moragon, J.J. Soler, S. Reyes, and M. Perpina Duration of length of stay in pneumonia: influence of clinical factors and hospital type Eur. Respir. J., October 1, 2003; 22(4): 643 - 648. [Abstract] [Full Text] [PDF]

				M. E. Singer, I. Harding, M. R. Jacobs, and D. H. Jaffe Impact of antimicrobial resistance on health outcomes in the out-patient treatment of adult community-acquired pneumonia: a probability model J. Antimicrob. Chemother., May 1, 2003; 51(5): 1269 - 1282. [Abstract] [Full Text] [PDF]

				M Woodhead Assessment of illness severity in community acquired pneumonia: a useful new prediction tool? Thorax, May 1, 2003; 58(5): 371 - 372. [Full Text] [PDF]

				P.P. Espana, A. Capelastegui, J.M. Quintana, A. Soto, I. Gorordo, M. Garcia-Urbaneja, and A. Bilbao A prediction rule to identify allocation of inpatient care in community-acquired pneumonia Eur. Respir. J., April 1, 2003; 21(4): 695 - 701. [Abstract] [Full Text] [PDF]

				M. Woodhead Community-acquired pneumonia in Europe: causative pathogens and resistance patterns Eur. Respir. J., July 1, 2002; 20(36_suppl): 20S - 27s. [Abstract] [Full Text] [PDF]

				BTS Guidelines for the Management of Community Acquired Pneumonia in Adults Thorax, December 1, 2001; 56(90004): iv1 - 64. [Full Text] [PDF]

				M. Falguera, O. Sacristan, A. Nogues, A. Ruiz-Gonzalez, M. Garcia, A. Manonelles, and M. Rubio-Caballero Nonsevere Community-Acquired Pneumonia: Correlation Between Cause and Severity or Comorbidity Arch Intern Med, August 13, 2001; 161(15): 1866 - 1872. [Abstract] [Full Text] [PDF]